Overview of Opioid Epidemic Act

Pete Wertheim, MS
AOMA Executive Director
Disclosures: None
June 1, 2017 – Arizona Department of Health Services (DHS) reports 790 people died in 2016 as a result of opioid overdoses, a 74% increase in four years

June 5, 2017 – Governor Doug Ducey Declares State of Emergency

September 5, 2017 – DHS releases Opioid Action Plan, includes numerous legislative recommendations

January 9, 2018 – Governor Ducey announces call for special session in his State of the State Address

January 22, 2018 – Special session begins

January 25, 2018 – SB 1001, Opioid Epidemic Act passes unanimously by House & Senate
The opioid epidemic continues to grow significantly in Arizona with more than 1,125 suspected overdose deaths and 7,007 overdoses reported since June 15, 2017 to April 12, 2018 (Department of Health Services Website).

The opioid epidemic has been at the forefront in the news locally and nationally, it is an emergent priority issue for policymakers everywhere.

Unprecedented and sweeping policy changes impacting physician pain management and prescribing practices are being imposed in Arizona and many states.

Rightly or wrongly, physicians are held responsible for initiating and prolonging the opioid epidemic so aggressive legislative reforms were inevitable.
Physician Advocacy

• Physicians are deeply committed to ending the opioid epidemic in Arizona

• AOMA and the Arizona Medical Association (ArMA) engaged in partnership with the Governor, Arizona legislators, and DHS as proactive and supportive stakeholders

• Through this partnership, AOMA and ArMA physicians, staff, and lobbyists worked tirelessly to advocate for compassionate legislative provisions to protect vulnerable patients; examples include exceptions for patient types/circumstances, delayed effective dates for implementation, and additional substance abuse treatment resources

• AOMA and ArMA successfully advocated for significant reforms to be included in SB 1001 to limit restrictive prior authorization policies by health plans to improve access to non-opioid therapies
AOMA Statement on Opioid Epidemic Act
“The AOMA is committed to ending the opioid crisis and we support Governor Ducey’s proposed legislation to address the opioid epidemic. Physicians are deeply concerned about the growth and prevalence of opioid abuse/misuse and related fatalities from overdoses. We will continue working with the Governor and policymakers to ensure these legislative reforms are successfully implemented and achieve all of the desired goals and objectives.”

Next Steps
• Educating physicians and implementing provisions of SB 1001 Opioid Epidemic Act; unless specified otherwise, provisions go into effect April 26, 2018
• If necessary, seek amendments to legislative provisions in 2019 if significant problems arise
• There will be substantial administrative rulemaking necessary to define and implement the new laws
The Opioid Epidemic Act is complex – we strongly recommend setting aside time to understand the new laws and preparing in advance of its implementation; most of its provisions will go into effect April 26, 2018.

If you are unclear about the law and its provision, make sure to review the text of the actual legislation for guidance and consult an attorney if necessary; do not solely rely on summaries, news articles, etc. for implementation.

The remaining slides in this slide deck summarize the major provisions in the bill; although it is comprehensive some minor details may be missing or excluded.
1. 5-day Initial Fill Limit
2. 90 MME Dosage Limits
3. “Trailer Bill” to Fix Opioid Epidemic Act
4. Electronic Prescribing
5. Medical Education
6. Prescription Monitoring Program
7. Regulation of Pain Management Clinics
8. Dispensing & Pain Management
11. Medication Assisted Treatment
12. Public Safety
13. Substance Abuse Initiatives
5-day Initial Fill Limit

- Limits “initial prescriptions” to all patients for a Schedule II opioid controlled substances to a 5-day supply; similar 14-day limit following a surgical procedure; regulatory boards may be more restrictive
- Defines “initial prescription” as a Schedule II opioid controlled substance that has not been dispensed to the patient during the previous 60 days, confirmed by the Controlled Substances Prescription Monitoring Program (PMP)
- Provides the following exceptions to the initial fill limitation when the patient:
  - Has an active oncology diagnosis
  - Has a traumatic injury, not including a surgical procedure
  - Is receiving hospice care
  - Is receiving end-of-life care
  - Is receiving palliative care
  - Is receiving skilled nursing facility care
  - Is receiving treatment for burns
  - Is receiving medication assisted treatment (MAT) for a substance abuse disorder
  - Is an infant being weaned off opioids at the time of hospital discharge
90 MME Dosage Limits

- Prohibits healthcare providers from issuing a new prescription order that exceeds 90 morphine milligram equivalents (MME) per day; exceptions include:
  - Continuation of prior prescription order within the previous 60 days
  - An opioid with a maximum approved total daily dose in the labeling as approved by the FDA; exemption is for “atypical opioids” with doses regulated by the federal government
  - A patient who:
    - Has an active oncology diagnosis
    - Has a traumatic injury, not including a surgical procedure
    - Is receiving hospice care
    - Is receiving end-of-life care
    - Is receiving palliative care
    - Is receiving skilled nursing facility care
    - Is receiving treatment for burns
    - Is receiving MAT for a substance abuse disorder
    - Is hospitalized
Exceptions for Other Patients

- A healthcare professional may issue a new prescription above 90 MME to a nonexempt patient after first consulting with a physician who is board-certified in pain; if consulting physician is not available within 48 hours of the request the healthcare professional may prescribe and subsequently have the consultation; teleconference consultation is permissible.

- Physicians who are board-certified in pain may issue a prescription order above 90 MME without a consultation; the licensing boards need to define what “board-certified in pain” since it is not defined in the legislation.

Naloxone

- If a patient is issued a new prescription above 90 MME per day, the prescriber must also prescribe Naloxone or other opioid antagonists.
HB 2549 “Trailer Bill” to Fix Opioid Epidemic Act

HB 2549 controlled substances; dosage limit (Rep. Carter)

- Exempts prescriptions capped at a 14-day supply that are issued following a surgical procedure from the 90 MME per day limitation
- Clarifies that the 90 MME limit only applies to prescriptions that are filled or dispensed outside of a health care institution
- Exempts implantable devices from the prohibition on opioid dispensing
- Permits the Arizona Poison Control System to provide opioid assistance and referral resources through a toll-free telephone service, including consults or referrals for 90 MME prescriptions
Opioid Assistance + Referral Line for Arizona Providers: 1-888-688-4222

- Patients taking high numbers of MME
- Patients that require an exit strategy from their current opioid regimen (including tapering)
- New patients on multiple controlled substances
- Challenging patients with pain and mental health/substance use comorbidities
- Patients with acute opioid overdose or toxicity
- Patients with acute opioid or benzodiazepine withdrawal
- Patients that require MAT
- Patients that require local referrals to behavioral health or substance use disorder treatment
Electronic Prescribing

Mandated Use
• Beginning January 1, 2019, requires e-prescribing to dispense Schedule II opioid controlled substances in Maricopa and Pima counties; exception for MAT
• Beginning July 1, 2019, requires e-prescribing to dispense Schedule II opioid controlled substances in all other counties; exception for MAT

Exceptions
• Requires the Arizona Board of Pharmacy to establish a process to grant waivers from e-prescribing requirements due to lack of broadband access or hardship

Gap Analysis
• Requires the Arizona Board of Pharmacy to provide a report to the Governor and Legislature by September 1, 2018 on the ability of prescribers to access and use e-prescribing to comply with these requirements
Medical Education

Medical School Requirements
• Requires a student enrolled in a public or private medical program in this state and whose intended degree may make the student eligible for a United States Drug Enforcement Administration registration to take at least three hours of opioid-related clinical education
  o DHS Statewide Health Professional Education Programs' Curriculum Development

Continuing Medical Education
• Requires a healthcare professional authorized to prescribe Schedule II controlled substances or who is authorized to dispense (pharmacists) controlled substances to complete a minimum of three hours of opioid-related continuing medical education each license renewal cycle as part of their existing requirements
**Prescription Monitoring Program (PMP)**

**Removal of 5-day Exemption**
- Eliminates from the current list of PMP review exemptions prescriptions under 5-days when the PMP had been checked within the previous 30 days

**Enforcement**
- Provides unconditional access to the PMP to the health licensing boards; previously they must have an open investigation or complaint to retrieve the information

**Pharmacists Mandated Use**
- Requires pharmacists to be registered and have access to the PMP
  - Before dispensing a Schedule II controlled substance, pharmacists shall obtain a PMP report for the proceeding 12 months; allows for waivers for technological limitations or exceptional circumstances out of their control
  - Allows licensed pharmacy technician trainees, pharmacy technicians or pharmacy interns to serve as delegates to pharmacists
Regulation of Pain Management Clinics

Licensure & Applicability
• Beginning January 1, 2019, requires pain management clinics to meet the same licensure requirements as other DHS licensed healthcare facilities; additional requirements for informed consent, medical director responsibilities, annual record keeping & reporting, and physical examination requirements
• Defines “Pain Management Clinic” as a healthcare institution or private office or clinic in which a majority of patients in any month are prescribed opioids, benzodiazepines, barbiturates or Carisoprodol for more than 90-days in a 12-month period; does not include MAT
• Pain management clinics must have a licensed physician or nurse practitioner with advanced certification with an unrestricted and unencumbered license to serve as the medical director
• Rules expected to be similar to other healthcare facility regulations; DHS will need to promulgate administrative rulemaking to implement
Dispensing & Pain Management

Prohibition Against Dispensing
• Prohibits healthcare professionals from dispensing Schedule II controlled substances that are opioids (act of unprofessional conduct); exception for MAT and implantable devices

Veterinarians
• Limits veterinarians from dispensing Schedule II controlled substances to 5-days; 14-days for benzodiazepines; 30 days limits after initial fills for chronic conditions

Red Cap Warning
• Requires that containers of Schedule II opioid controlled substances dispensed by a pharmacist include a red cap and warning label about potential addiction
Prior Authorization Reforms

Transparency & Technology

• Requires health plans to make available on their web-site or provider portal a listing of all prior authorization (PA) requirements; listing must clearly identify the specific services, drugs or devices to which a PA requirement exists, including specific information or documentation that a provider must submit in order for the PA request to be considered complete
• Requires the health plans to allow providers to access the prior authorization request through the applicable software system
• Specifies that the health plan or its utilization review agent must provide at least two forms of access to request a PA and must have emergency after-hours procedures
• Beginning January 1, 2020, the health plans must accept and respond to prior authorization requests for prescription benefits through a secure electronic transmission; provides exceptions for providers due to financial hardship or connectivity issues
Timeframes & Approval Process

• Establishes maximum timeframes for decisions on PAs:
  o For urgent health care services, the authorization or adverse determination must be no later than 5 days
  o For non-urgent health care services, the authorization or adverse determination must be no later than 14 days

• Requires the health plan or its utilization review agent to acknowledge receipt of the PA request and notification to the provider whether the PA request is granted, denied or incomplete

• If the request is denied the specific reason for the denial must be included. If the request is incomplete, the provider must have the option to submit additional information
Due Process

• If a PA request is incomplete, the provider must have the option to submit additional information; after additional information is submitted the health plan has 5 days to review and respond for urgent requests and 14 days for non-urgent requests.

• Specifies that PAs are deemed granted if there is failure to comply with the timeframes.

• States that PAs are binding and may not be rescinded once a decision is made; exception in cases of fraud or misrepresentation.

• Requires an appeal process in cases of denial of a PA request.
Duration & Conditions

• Specifies that a health plan must honor a PA that is granted for an approved drug for the earliest of the following:
  o Six months after the date of the PA approval
  o The last day of the enrollee’s coverage under the plan
• Allows health plans to request that the provider submit information indicating that the enrollee’s chronic pain condition has not changed and that the continuation of the treatment is not negatively affecting the enrollee’s health
• If the provider does not respond within 5 business days, the health plan or its utilization review agent may terminate the PA
Additional Factors

• States the PA time limits for chronic pain do not apply to prescription medications if the FDA recommends that the drug be used only for periods less than 6 months and any opioid or benzodiazepine or other Schedule I or II controlled substances.

• Allows for substitutions for a comparable brand product or a generic counterpart with therapeutic equivalence evaluations.

• Permits PAs for longer than six months.
Medication Assisted Treatment

Provision of MAT

• Requires structured sober living homes to develop policies and procedures to allow individuals on MAT to continue receiving the treatment while living in a structured sober living home
• Requires health plans to allow at least one medically-assisted treatment be available with prior authorization
• Defines “Medication Assisted Treatment” as the use of FDA approved medications in combination with counseling and behavioral health therapies to provide a whole patient approach to the treatment of substance abuse disorders
Public Safety

- Provides immunity from prosecution to persons who in good faith seek medical assistance for someone who experience an overdose or to persons experiencing an overdose; self repeals after June 30, 2023
- Removes eligibility for a suspended sentence, probation, pardon or released from confinement for the illegal manufacture, sale or marketing of opioids
- Requires veterinarians who suspect a person is trying to obtain controlled substances for intent other than to treat the intended animal to report to law enforcement within 48 hours after treatment or examination; provides civil immunity for reporting
- Adds trained ancillary law enforcement employees to the list of persons authorized to administer Naloxone or opioid antagonist through a standing order; may include detention officers, probation officer, police aide, etc.
- Requires the Governor’s Office of Youth, Faith and Family to report on the feasibility of a statewide expansion of the Arizona Angel Initiative, receiving substance support and turning over drugs without fear of arrest
Substance Abuse Initiatives

- Requires cities or towns to report 911 overdose calls and related overdose deaths to DHS
- Requires counties to establish a drop-off location for legal or illegal substances and drug paraphernalia; person may receive referral to a substance abuse treatment facility
- Beginning September 1, 2018, requires hospitals and healthcare facilities to report quarterly to DHS the following:
  - Locations and types of facilities where substance abuse treatment is provided
  - Number of available substance abuse treatment beds
  - Number of days facility was at capacity and unable to accept referrals
- Requires DHS to report substance abuse and treatment availability and capacity information to Governor and Legislature
- Requires DHS and the Governor’s Office of Youth, Faith and Family to develop a comprehensive opioid abuse prevention communications campaign
Substance Abuse Initiatives

- Requires healthcare institutions to refer a patient who is discharged after receiving emergency services for a drug-related overdose to a behavioral health services provider.
- Requires hospice service agencies to adopt policies and procedures to inform client families on the proper disposal of Schedule II controlled substances.
- Requires DHS and AHCCCS to provide Naxolone kits as necessary to county health departments to provide to persons at risk for opioid-related overdose.
- Establishes a Substance Abuse Disorder Services Fund through AHCCCS to enter into agreements with one or more contractors to provide additional services to Title XIX or Title XXI eligible recipients as payer of last resort; provides $10 million in FY 2017-2018 from the General Fund.
- Provides $400,600 to both DHS for an opioid abuse prevention campaign and the Attorney General to award community grants for opioid education and prevention efforts.
Next Steps

• Understanding and complying with the new law
  o Continuing Medical Education

• Implementation & Enforcement
  o Attorney General interpretation of provisions
  o Administrative rulemaking
  o Substantive policy statements
  o Accountability

• Accountability (e.g. gap analysis report on e-prescribing)

• Revisions
  o 2019 legislation, if necessary
Additional Help?

Have questions, suggestions or feedback you would like to share?

Please contact the Arizona Osteopathic Medical Association at 602-266-6699 or send an email to communications@az-osteo.org